Amag Pharmaceuticals has acquired global rights to develop and market digoxin immune Fab, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women.
Although digoxin immune Fab therapy may function similarly in a patient with decreased renal function, neither digoxin nor Fab can be removed by hemodialysis which was believed that it would complicate the removal of toxins and anesthesia further in this case [8].
Dialysis is an ineffective treatment for intoxication, but the administration of digoxin immune Fab is highly effective in life-threatening digoxin poisoning [74].
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.